In this study, we have developed a practical mouse model for evaluating in vivo the antiviral activity of compounds against respiratory syncytial virus (RSV) infection. BALB/c mice are not particularly susceptible to RSV infection; however, infection rates were improved by pretreatment with the immunosuppressive agent cyclophosphamide (CYP). When mice were inoculated intranasally with RSV A2 strain, the pulmonary RSV titres of CYP-pretreated 10-week-old mice were higher than those of untreated 10-week-old and 28-week-old mice, peaking on days 4 and 5 post-infection. Sections of lung from RSV-infected mice pretreated with CYP, taken on day 4 postinoculation, showed widespread evidence of interstitial pneumonia and other significant pathological changes. We also confirmed that ribavirin, a representative antiviral agent, significantly reduced the pulmonary RSV titres of mice pretreated with CYP when administered intraperitoneally.
Human respiratory syncytial virus (RSV), a member of the family Paramyxoviridae, is the most prevalent infectious agent causing acute lower respiratory illness in infants and young children. Presently, ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is the only drug administered to bronchopulmonary dysplasia patients for the chemotherapy of this severe virus-induced illness (Hall et al., 1985) . However, the dosage of this drug is limited in an aerosol treatment because of its efficacy and toxicity (Smith et al., 1991) .
Several new anti-RSV agents have shown potent antiviral activity in vitro (De Clercq et al., 1991; Shuto et al., 1992) and are being further evaluated in vivo in RSVinfected animals. The cotton rat (Sigmodon hispidus) has been used as an animal model for studying RSV infection (Wyde et al., 1990) . However, such animals are not readily available from commercial animal breeders. Although mice are desirable animal models because they are easy to handle, they are not as susceptible to infection with RSV. Some researchers have reported that older BALB/c mice are more susceptible than younger mice to RSV infection (Graham et al., 1988; Taylor et al., 1984) . In the present study, we have developed a practical mouse model for evaluating the antiviral activity of anti-RSV agents in vivo.
Materials and Methods

Animals, cells, viruses and compounds
Pathogen-free 10-week-old female BALB/c mice were purchased from Charles River Laboratories (Yokohama, Japan). Cotton rats (50-100 g) were obtained from the Experimental Animal Center, Fukushima University School of Medicine (Fukushima, Japan). All animals were housed in cages covered with barrier filters and were fed mouse chow and water ad libitum. HeLa cells were maintained in Eagle's minimum essential medium (MEM) supplemented with glutamine, gentamicin, penicillin G and 10% foetal bovine serum. RSV strain A2 was obtained from the ATCC. Ribavirin was provided by H Machida (Yamasa Corporation, Choshi, Japan). 
Mouse infection
Introduction
phamide (CYP; Nacalai Tesque, Tokyo, Japan) per kg of body weight 5 days before virus inoculation. On the day of inoculation (day 0), all mice were weighed, anaesthetized with sodium pentobarbital (50 mg/kg) and inoculated intranasally with approximately 10 5 plaque-forming units (p.f.u.) of RSV strain A2 in 50 µl. From days 1 through 3 post-infection, two groups of CYP-pretreated mice were given ribavirin i.p. three times per day; one group received 60 mg/kg body weight, while the other received 90 mg/kg body weight. On day 4, the day on which untreated mice showed the maximum pulmonary RSV titre, all mice were euthanized and their lungs removed, weighed and assayed for virus titres.
On the day of inoculation (day 0), all cotton rats were weighed, anaesthetized with sodium pentobarbital (50 mg/kg) and inoculated intranasally with approximately 10 5 p.f.u. of RSV strain A2 in 100 µl. On day 4, all cotton rats were euthanized and their lungs removed, weighed and assayed for virus titres.
Virus quantification
Both lungs were removed from mice and cotton rats and were homogenized using a glass homogenizer with a Teflon pestle (Ikemoto Scientific Technology, Tokyo, Japan) in 4 ml of Hanks' balanced salt solution supplemented with 0.218 M sucrose, 4.4 mM glutamate, 3.8 mM KH 2 PO 4 and 3.2 mM K 2 HPO 4 as described previously (Piazza et al., 1993) . The resulting suspensions were stored at -70°C prior to assay. HeLa cells were seeded into a 24-well tissue culture plate (Falcon 3074, Becton Dickinson) at approximately 2×10 5 cells/well and incubated at 37°C in 5% CO 2 . Lung homogenates were diluted (10-fold) using Eagle's MEM supplemented with 2% foetal calf serum (Cell Culture Laboratories, Cleveland, Ohio, USA), 100 units/ml penicillin G and 100 µg/ml streptomycin. Each dilution of the homogenate was tested for virus titre in confluent HeLa cells. After incubation for 5 days at 35°C, all plates were treated with 5% (v/v) formaldehyde/PBS solution, and immunostaining was performed according to the modified protocol of Murphy et al. (1990) . The wells were incubated first with 5% Fraction V in PBS for 30 min at 37°C, then with a horseradish peroxidase-conjugated anti-RSV serum (ViroStat, Portland, Me., USA) diluted (20-fold) with 1% Fraction V in PBS for 1 h at 37°C. After the plates were washed twice with 5% Fraction V in PBS, the wells were incubated with a 4 CN membrane peroxidase substrate (Kirkegaard & Perry Laboratories, Gaithersburg, Md., USA) at room temperature for optimum colour development. Finally, the RSV plaques were counted.
Histological methods and evaluation
Lungs removed for histological examination were placed in buffered formalin for a minimum of 24 h. The tissue was stained and evaluated by A Ichikawa (Fuji Biomedix, Yamanashi, Japan). The tissue was then embedded in lowmelting point paraffin, sectioned at a thickness of 5 µm and stained with haematoxylin and eosin. The stained sections CYP-pretreated 10-week-old mice ( ), untreated 10-week-old mice ( ), untreated 28-week-old mice ( ). Mice were killed on days 2-7 after virus infection. Each point represents the geometric mean virus titre (log 10 ) of four to eight animals. 
Statistical analysis
The geometric means of virus titres from the experimental groups were compared with those from the control groups using the Mann-Whitney U-test. A P value of 0.05 or less was considered to be significant.
Results
Replication of RSV in mouse lungs
The BALB/c mice were not susceptible to any of three clinical isolates of RSV or to the standard long strain of RSV (data not shown), but were susceptible to the A2 strain, especially after pretreatment with the immunosuppressive agent CYP. As shown in Figure 1 , we compared the virus titres in the lungs of mice pretreated with CYP, untreated (control) mice and cotton rats. The average pulmonary RSV titre of pretreated mice was only slightly lower than that of cotton rats. However, the average pulmonary RSV titre of pretreated mice was much higher than that of control mice.
We also investigated RSV infection in older mice, because it was previously reported that RSV replicates better in old mice than in young mice (Graham et al., 1988; Taylor et al., 1984) . Although RSV replication in the lungs of 28-week-old mice was slightly greater than that in the lungs of 10-week-old mice, the pulmonary titres were inadequate to evaluate antiviral effects in vivo (Figure 2) . Administration (i.p.) of CYP (100 mg/kg ) to 10-weekold mice 5 days before virus inoculation significantly increased the pulmonary virus titres compared with those of 10-week-old or 28-week-old untreated mice (Figure 2 ). The titres of 10-week-old CYP-pretreated mice peaked on day 4 and day 5 (3.93±0.10 and 3.97±0.21 log 10 p.f.u./g of lung), but declined rapidly on day 6. These data suggest that pretreatment with CYP increases the susceptibility of mice to RSV infection, enhancing their usefulness as an in vivo model for evaluating anti-RSV compounds. Figure 3 shows a histological photograph of a lung from an uninfected 10-week-old mouse and a lung from an RSVinfected 10-week-old mouse, pretreated with CYP, on day 4 post-infection. Nearly all sections of the RSV-infected lung showed evidence of interstitial pneumonia. Mononuclear cells and eosinophil infiltration were detected in the peribronchiolar and perivascular spaces. There was thickening of the alveolar walls and arteritis followed by monocyte infiltration in the artery. Neutrophils and giant cells were identified in the alveolar walls. Alveolar oedema was also detected. Clearly, mice pretreated with CYP undergo significant pathological changes of the pulmonary tissues as a result of RSV infection.
Histological findings
Effect of ribavirin on RSV-infected mice
The anti-RSV activity of ribavirin was evaluated using our mouse model (Figure 4) . Administration (i.p.) of ribavirin significantly reduced the pulmonary virus titres: a dose of 60 mg/kg three times a day for three days reduced the titre to 30% of the control, and a dose of 90 mg/kg three times a day for three days reduced the titre to 9% of the control. These results indicate that mice infected with RSV followAntiviral Chemistry & Chemotherapy 10:3 3 ing pretreatment with CYP effectively serve as a useful animal model for evaluating anti-RSV agents such as ribavirin in vivo.
Discussion
Previously, the in vivo evaluation of anti-RSV agents has been carried out using the cotton rat model (Gruber et al., 1987; Prince et al., 1990; Wyde et al., 1990) . In addition, in vivo evaluation using ferrets (Prince & Porter, 1976) and primates (Belshe et al., 1977) has been reported. However, animals other than the cotton rat are much more difficult to use for antiviral drug evaluation. The cotton rat has been a singularly useful model and has provided data concerning pulmonary replication of viruses, protection and circulating antibody response (Prince et al., 1983) . Unfortunately, cotton rats are no longer available from breeders. Mice are desirable animal models because of their ease of handling, but they are not readily susceptible to RSV infection. However, their age may make a difference. Graham et al. (1988) reported that mice from 8 to 10 months old were more susceptible to RSV infection than those aged 8 weeks old. We found that immunosuppression with CYP made an even bigger difference in susceptibility. Thus, the immunosuppressed RSV-infected mouse model was chosen for study because it is the most practical model in which infection can take place throughout the life of the animal and because viral titres of approximately 10 4 p.f.u./g of lung may be attained, a level that is more than sufficient for evaluating antiviral effects. Titres in pulmonary tissues reached their maximum approximately 4 days after inoculation and rapidly diminished on day 6. Moreover, sections of lung from RSV-infected mice pretreated with CYP, taken on day 4 post-inoculation, revealed the following histological evidence of interstitial pneumonia: (i) mononuclear cell and eosinophil infiltration in peribronchiolar and perivascular spaces; (ii) thickening of alveolar walls; and (iii) arteritis followed by monocyte filtration in the artery.
Ribavirin has been successfully administered by continuous small-particle aerosol to humans (Fernandez et al., 1986; Hall et al., 1983) and cotton rats (Hruska et al., 1982; Wyde et al., 1986) infected with RSV. Ribavirin was shown to be significantly more efficacious when delivered by this method than when given i.p. (Hruska et al., 1982) . In the cotton rat model, ribavirin aerosol reduced the amount of virus in lung tissue by more than 90% (Gilbert et al., 1993; Wyde et al., 1987) . In our study, 60 mg/kg and 90 mg/kg doses of ribavirin showed significant pulmonary titre reduction when administered i.p. three times per day for three days. Pulmonary RSV titres in 90 mg/kg ribavirintreated mice showed a large standard deviation. However, ribavirin had no effect when administered only once a day for three days. Evidently, the efficacy of ribavirin is dosedependent.
In our study, CYP was administered i.p. 5 days before RSV infection. Our results indirectly suggested that CYP reduced the number of leukocytes in mice to a minimum on day 5 post-administration, supporting the results reported by Ikeda et al. (1990) . We also tested two other immunosuppressive agents used in other reported infection experiments, to determine whether they would improve the efficiency of RSV infection in mice. Anti-asialo GM.1 antibody depletes natural killer cells in mice and treatment with this agent is known to raise the efficiency of murine cytomegalovirus infection (Ikeda et al., 1993) . This agent was given to mice i.p. at 100 mg/kg either 1 day or 4 days before RSV infection; however, treatment did not affect pulmonary RSV titres (data not shown).
i-Carrageenan reportedly blocks the function of macrophages, especially in mice (Sarwar, 1987) . At 100 mg/kg, i-carrageenan was given to mice i.p. 1 day before RSV infection. Our study showed that treatment with icarrageenan raised the pulmonary virus titre to a degree similar to that found in mice treated with CYP. However, all mice given i-carrageenan showed a reduction in body weight (data not shown), making this agent unsuitable for the mouse model of RSV infection that we aimed to establish.
Our mouse model of RSV infection has several advan- tages: (i) handling of mice is easier than that of cotton rats; (ii) BALB/c mice are readily available from commercial breeders; and (iii) mice can be purchased by age and sex to obtain stable data. The mouse model we have established appears to be beneficial for evaluating in vivo the antiviral activity of compounds against RSV infection.
